Antinociceptive action of quipazine: relation to central serotonergic receptor stimulation.
Quipazine, a serotonin receptor stimulant, inhibited the response of rats to painful stimuli in two methods currently used to measure antinociception in these animals: the hot plate and tail compression test. The antinocicptive action was observed with doses ranging from 5 to 20 mg/kg i.p according to the test situation. The effect was significantly antagonized by a pretreatment with methergoline, a potent serotonin antagonist. An electrolytic lesion placed in the nucleus raphe medianus, which produced a marked decrease of serotonin in the forebrain did not, or only slightly, affected the effect of quipazine, depending on the method used to measure antinociception. It is suggested that quipazine can produce antinociceptive action in rats by interacting with a serotonergic mechanism. The action appears to be due mainly to a direct action on postsynaptic serotonin receptors, although a presynaptic component can also contribute to the effect of quipazine.
D000698:Analgesia; D000818:Animals; D001921:Brain / Q000378:metabolism; D005260:Female; D008636:Mesencephalon / Q000502:physiology; D008711:Metergoline / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011804:Quinolines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D017981:Receptors, Neurotransmitter / Q000187:drug effects; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists
D010879:Piperazines; D011804:Quinolines; D017981:Receptors, Neurotransmitter; D012702:Serotonin Antagonists; D008711:Metergoline; D012701:Serotonin